Premium
Frontline treatment with the combination obinutuzumab ± chlorambucil for chronic lymphocytic leukemia outside clinical trials: Results of a multinational, multicenter study by ERIC and the Israeli CLL study group
Author(s) -
Herishanu Yair,
Shaulov Adir,
Fineman Riva,
BašićKinda Sandra,
Aviv Ariel,
WasikSzczepanek Ewa,
Jaksic Ozren,
Zdrenghea Mihnea,
Greenbaum Uri,
Mandac Inga,
Simkovic Martin,
Morawska Marta,
Benjamini Ohad,
Spacek Martin,
Nemets Anatoly,
Bairey Osnat,
Trentin Livio,
Ruchlemer Rosa,
Laurenti Luca,
Stanca Ciocan Oana,
Doubek Michael,
Shvidel Lev,
Dali Nagib,
Mirás Fátima,
De Meûter Anne,
Dimou Maria,
Mauro Francesca R.,
Coscia Marta,
Bumbea Horia,
Szász Róbert,
Tadmor Tamar,
Gutwein Odit,
Gentile Massimo,
Scarfò Lydia,
Tedeschi Alessandra,
Sportoletti Paolo,
Gimeno Vázquez Eva,
Marquet Juan,
Assouline Sarit,
Papaioannou Maria,
Braester Andrei,
Levato Luciano,
Gregor Michael,
Rigolin Gian M.,
Loscertales Javier,
Medina Perez Angeles,
Nijziel Marten R.,
Popov Viola M.,
Collado Rosa,
Slavutsky Irma,
Itchaki Gilad,
Ringelstein Shimrit,
Goldschmidt Neta,
Perry Chava,
Levi Shai,
Polliack Aaron,
Ghia Paolo
Publication year - 2020
Publication title -
american journal of hematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.456
H-Index - 105
eISSN - 1096-8652
pISSN - 0361-8609
DOI - 10.1002/ajh.25766
Subject(s) - obinutuzumab , chlorambucil , medicine , ibrutinib , ighv@ , rituximab , oncology , gastroenterology , surgery , chronic lymphocytic leukemia , leukemia , chemotherapy , lymphoma , cyclophosphamide
In recent years, considerable progress has been made in frontline therapy for elderly/physically unfit patients with CLL. The combination of obinutuzumab and chlorambucil (O‐Clb) has been shown to prolong progression free survival (PFS, median PFS‐31.5 months) and overall survival (OS) compared to chlorambucil alone. More recently, obinutuzumab given in combination with either ibrutinib or venetoclax improved PFS but not OS when compared to O‐Clb. In this retrospective multinational, multicenter co‐operative study, we evaluated the efficacy and safety of frontline treatment with O ± Clb in unfit patients with CLL, in a “real‐world” setting. Patients with documented del (17p13.1)/ TP53 mutation were excluded. A total of 437 patients (median age, 75.9 years; median CIRS score, 8; median creatinine clearance, 61.1 mL/min) were included. The clinical overall response rate was 80.3% (clinical complete and partial responses in 38.7% and 41.6% of patients, respectively). Median observation time was 14.1 months and estimated median PFS was 27.6 months (95% CI, 24.2‐31.0). In a multivariate analysis, high‐risk disease [del (11q22.3) and/or IGHV‐unmutated], lymph nodes of diameter > 5 cm, obinutuzumab monotherapy and reduced cumulative dose of obinutuzumab, were all independently associated with shorter PFS. The median OS has not yet been reached and estimated 2‐year OS is 88%. In conclusion, in a “real‐world” setting, frontline treatment with O‐Clb achieves PFS comparable to that reported in clinical trials. Inferior outcomes were noted in patients with del (11q22.3) and/or unmutated IGHV and those treated with obinutuzumab‐monotherapy. Thus, O‐Clb can be still considered as legitimate frontline therapy for unfit CLL patients with low‐risk disease.